ITGB2

(redirected from LFA-1)
Also found in: Acronyms, Wikipedia.

ITGB2

A gene on chromosome 21q22.3 that encodes an integrin beta chain family protein (integrins are noncovalently associated transmembrane glycoprotein receptors, composed one of 18 different alpha and one of 8 different beta chains). The beta chain encoded by ITGB2 can combine with multiple alpha partners to give rise to different integrins—e.g., with the alpha L chain to form the integrin LFA-1, or with the alpha M chain to form the integrin Mac-1. Integrins participate in cell adhesion as well as cell surface-mediated signalling.

Molecular pathology
ITGB2 mutations cause leukocyte adhesion deficiency type I.
References in periodicals archive ?
After six weeks, the heavy-duty LFA-1 doesn't show any wear on the exterior, while the inside shows the usual scuffs and cuts from having a pistol holstered and drawn numerous times per day and many times while on range trips.
biotechnology and pharmaceutical companies are now developing ICAM-1 and LFA-1 antibodies for clinical use, Isobe says.
LFA-1 regulates T-cell adhesion, migration, proliferation, and cytokine production.
Jim Mullen, Biogen's Chairman and Chief Executive Officer, noted, "The strength of our collaboration and ICOS' ability to move rapidly and efficiently, places ICOS in a strong position to move forward with the LFA-1 program.
The LFA-1 inhibitor product candidate, which was discovered at Sunesis, has the potential to address immunological and inflammatory diseases, including dry eye syndrome.
LFA-1 (Leukocyte Function-associated Antigen-1) is a cell adhesion molecule that promotes T-cell migration and activation that can lead to inflammatory diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis, and organ transplant rejection.
In January of this year, Sunesis announced the out-licensing of worldwide rights to patents and know-how related to Sunesis' LFA-1 inhibitor program to SARcode in exchange for license fees, convertible notes, milestone payments as well as potential royalty payments.
LFA-1 (Leukocyte Function-associated Antigen-1) is a cell adhesion molecule that promotes T-cell migration and activation that can lead to certain inflammatory conditions such as psoriasis, rheumatoid arthritis, multiple sclerosis and solid organ transplant rejection.
announced today the out-license of the company's LFA-1 inhibitor program to SARcode Corporation, a privately-held biopharmaceutical company.
ICOS Corporation (Nasdaq:ICOS) announced today the acquisition from Abbott Laboratories of additional rights for technology and compounds in inflammation in the field of LFA-1 antagonism.
today announced the conclusion of its collaboration with ICOS Corporation to develop LFA-1 (Leukocyte Function-associated Antigen-1) antagonists.
Nasdaq: BGEN) announced today their agreement to collaborate worldwide on the development and commercialization of orally active, small molecule LFA-1 antagonists (including ICOS' IC747, currently in a Phase 1 clinical trial) as oral therapeutics for the treatment of inflammatory conditions.